Home › Funds › GW HENSSLER & ASSOCIATES LTD › REGN

GW HENSSLER & ASSOCIATES LTD position in REGN

REGENERON PHARMACEUTICALS · Health Care

GW HENSSLER & ASSOCIATES LTD reported holding 24,179 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$18.3M, representing 0.80% of its reported portfolio and ranking #50 among its reported holdings. GW HENSSLER & ASSOCIATES LTD has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)24.18K sh
Reported value held$18.33M
Portfolio Weight0.80%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How GW HENSSLER & ASSOCIATES LTD's REGN position evolved

GW HENSSLER & ASSOCIATES LTD first disclosed a stake in REGN in Q3 2023 at 20,479 shares (US$16.9M). The position peaked in Q2 2024 at 18,545 shares, worth US$19.5M. Across 13 filings, GW HENSSLER & ASSOCIATES LTD increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 24,179 shares valued at US$18.3M — a reduction of -147 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 20.48K $16.85M New
Q4 2023 19.95K $17.52M Reduce
Q1 2024 19.45K $18.72M Reduce
Q2 2024 18.55K $19.49M Reduce
Q3 2024 18.07K $18.99M Reduce
Q4 2024 17.82K $18.73M Reduce
Q1 2025 20.36K $12.91M Add
Q2 2025 21.48K $11.28M Add
Q3 2025 24.22K $13.62M Add
Q4 2025 24.44K $18.87M Add
Q1 2026 23.93K $18.49M Reduce
Q2 2026 24.33K $15.17M Add
Q3 2026 24.18K $18.33M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has GW HENSSLER & ASSOCIATES LTD held REGN?

GW HENSSLER & ASSOCIATES LTD has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is GW HENSSLER & ASSOCIATES LTD's current position in REGN?

As of Q3 2026, GW HENSSLER & ASSOCIATES LTD holds 24.18K shares of REGN (REGENERON PHARMACEUTICALS), valued at $18.33M, representing 0.80% of its reported portfolio and ranking #50.

Has GW HENSSLER & ASSOCIATES LTD been buying or selling REGN?

In the latest 13F filing (Q3 2026), GW HENSSLER & ASSOCIATES LTD reduced its position in REGN. The position peaked in Q2 2024 at 18.55K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.